You are here
Angiochem has and will continue to form strategic alliances with companies and organizations to further apply its EPiC platform technology, advance development of its EPiC drug candidates and access complementary research, technology and development capabilities.
Collaboration with GlaxoSmithKline
Angiochem and GSK have established a collaboration to discover, develop and commercialize treatments for lysosomal storage diseases (LSDs). The collaboration will combine Angiochem’s expertise in creating novel therapeutics that cross the blood-brain barrier (BBB) with the scientific, development and commercialization capability of GSK in rare diseases. Under the collaboration agreement, Angiochem will create new compounds (EPiC-enzymes) intended to penetrate the BBB and restore enzyme function in the central nervous system (CNS). Current enzyme replacement therapies are unable to restore enzyme function in the CNS and therefore fail to ameliorate neurological symptoms associated with LSDs. Administration of the resulting EPiC-enzyme drug candidates to patients is anticipated to result in brain penetration as well as systemic distribution, thereby addressing CNS as well as peripheral symptoms of LSDs.